Teva Pharmaceutical Industries (TEVA) Long-Term Deferred Tax (2014 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Long-Term Deferred Tax came in at $2.2 billion in Q2 2026, up 21.39% YoY from $1.8 billion in Q2 2025, and down 1.28% on a QoQ basis from $2.2 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Long-Term Deferred Tax (2014 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 13 years of Long-Term Deferred Tax data on file, last reported at $2.2 billion in Q2 2026.
- Quarterly Long-Term Deferred Tax rose 21.39% year-over-year to $2.2 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.2 billion (up 21.39% YoY) and the FY2025 annual result came in at $2.2 billion, up 21.79% from the prior year.
- Long-Term Deferred Tax retreated to $2.2 billion in Q2 2026, from $2.2 billion in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $2.2 billion in Q4 2025 to a low of $637.0 million in Q1 2022.
- A 5-year average of $1.8 billion and a median of $1.8 billion in 2025 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2022 — Long-Term Deferred Tax surged 148.55% — and 2025, when it fell 21.06%.
- Tracing TEVA's Long-Term Deferred Tax over 5 years: stood at $1.5 billion in 2022, then rose by 24.28% to $1.8 billion in 2023, then retreated by 0.72% to $1.8 billion in 2024, then climbed by 21.79% to $2.2 billion in 2025, then declined by 1.32% to $2.2 billion in 2026.
- The last three Long-Term Deferred Tax figures came in at $2.2 billion (Q2 2026), $2.2 billion (Q1 2026), and $2.2 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.16 Bn |
| Mar 31, 2026 | 2.19 Bn |
| Dec 31, 2025 | 2.19 Bn |
| Sep 30, 2025 | 1.63 Bn |
| Jun 30, 2025 | 1.78 Bn |
| Mar 31, 2025 | 1.76 Bn |
| Dec 31, 2024 | 1.80 Bn |
| Sep 30, 2024 | 2.07 Bn |
| Jun 30, 2024 | 2.00 Bn |
| Mar 31, 2024 | 1.96 Bn |
| Dec 31, 2023 | 1.81 Bn |
| Sep 30, 2023 | 1.76 Bn |
| Jun 30, 2023 | 1.58 Bn |
| Mar 31, 2023 | 1.58 Bn |
| Dec 31, 2022 | 1.46 Bn |
| Sep 30, 2022 | 1.55 Bn |
| Jun 30, 2022 | 1.60 Bn |
| Mar 31, 2022 | 637.00 Mn |
| Dec 31, 2021 | 596.00 Mn |
| Sep 30, 2021 | 622.00 Mn |